MedTrace Logo

Topical Timolol: a Comparison of Surgical Outcomes

NCT05114239 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-11-09

No results posted yet for this study

Summary

The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the literature. The investigators will enroll 30 participants in a split scar study who have their skin cancer surgically removed resulting in a linear wound equal to or longer than 4cm. The objective of this randomized study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in wound closed primarily greater than or equal to 1.5 cm.

Conditions

  • Wound Heal

Interventions

DRUG

Timolol 0.25% Ophthalmic Solution

Applied to treatment side prior to standard wound care

OTHER

Standard Wound Care

Wound is washed twice a day with soap and then petrolatum and a bandage is applied.

Sponsors & Collaborators

  • Keith G. LeBlanc, Jr, MD

    lead OTHER

Principal Investigators

  • Keith G LeBlanc, MD · LSU HSC New Orleans

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-07
Primary Completion
2022-09-30
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05114239 on ClinicalTrials.gov